Junyuan Biotech Completes Tens of Millions of RMB in Angel Funding to Advance Global Access to Innovative Molecular Diagnostics

VCBeat has learned that Junyuan Biology recently announced the completion of its angel financing round, amounting to tens of millions of yuan. Led by Yanghe Investment, the funds will be allocated to the continuous R&D of innovative molecular diagnostic technologies, facility construction, and team expansion, laying a solid foundation for the development and translation of clinical products.

Junyuan Biotechnology was established in 2020 by Dr. Wen Gang Zhou, who holds a Ph.D. from the United States in the field of biomedicine. Dr. Zhou has nearly 10 years of work and management experience in the domestic and international biopharmaceutical industry, as well as 20 years of R&D experience in genomics and bioinformatics. He previously served as Chief Scientist at Pfizer (USA), Deputy General Manager at Amoy Diagnostics, and General Manager at Shanghai Xiawei. During his tenure, he led teams to develop numerous molecular diagnostic products, with several companion diagnostic products advancing to the registration stage for Class III medical devices.

Junyuan Biotechnology focuses on the molecular diagnostics sector, driving product innovation through numerous independently developed breakthrough technology platforms to meet the growing clinical demand for complex testing. The company is dedicated to developing precision diagnostic products that represent the forefront of clinical diagnosis and treatment, filling gaps in both domestic and international markets, thereby benefiting tens of millions of cancer and infectious disease patients across China.

As a diverse array of therapeutic modalities—including macromolecules, small molecules, immunotherapy, cell therapy, and gene therapy—rapidly emerge, clinical demand for precision medicine is growing significantly, ushering the molecular diagnostics industry into a period of rapid development. Furthermore, national policies have been introduced to encourage private hospitals, blood station systems, primary healthcare institutions, and disease control and prevention agencies to establish nucleic acid testing laboratories. This provides an opportunity for the more rapid and widespread implementation of precision medicine at the grassroots level, with the market size of molecular diagnostics expected to expand at an accelerated pace.

Meanwhile, as diseases have become increasingly complex in recent years, management has grown more refined, and drug varieties and treatment strategies have diversified, clinical demands for diagnostic technologies have further escalated. It is therefore imperative for the molecular diagnostics industry to leverage technological innovation and breakthroughs to deliver cost-effective, high-accuracy products that address current and future rigid clinical needs, thereby fostering further industry development and widespread clinical adoption of these products.

Junyuan Biologics is committed to meeting actual clinical needs. Its independently developed, breakthrough molecular diagnostics technology platform, J-STAR, addresses the limitations of existing technical platforms, resolves complex clinical testing requirements through technological innovation, and fills multiple market gaps. Furthermore, this technology offers high scalability, enabling broad coverage of currently unmet clinical application scenarios in the molecular diagnostics field that feature substantial clinical demand, potential for differentiation, and competitive advantages.

Following the completion of this financing round, the Company will continue to upgrade and expand its J-STAR technology platform, strengthen clinical validation as well as data accumulation and mining capabilities, and accelerate both pipeline expansion and product registration and approval processes. These efforts aim to promote the widespread adoption of precision medicine, make it accessible to the general population at the grassroots level, enable patients in hospitals at all levels to benefit from more precise medical products and services, and ultimately improve patients’ quality of life and survival outcomes.

Dr. Zhou Wengang, Founder of Junyuan Bio, stated, “We appreciate the investors’ recognition and support for Junyuan Bio. As national healthcare reform policies continue to deepen, centralized procurement of drugs and consumables becomes normalized, and policies such as DRG are successively implemented, the capital market has paid particular attention to the development of the in vitro diagnostics (IVD) industry, especially against the backdrop of the COVID-19 pandemic. Junyuan Bio boasts substantial technological reserves, product expertise, and industry resources in the molecular diagnostics sector. We have a thorough understanding of the upstream and downstream industry chains, and our core technologies feature broad clinical application scenarios and strong cross-platform scalability. Leveraging internationally leading innovative technologies, we aim to deliver our advantageous and cutting-edge diagnostic products to more patients in China and around the world.”

Fu Chao, Vice President of the Investment Department at Yanghe Investment, stated, “Given China’s current stage of development and the payment mechanisms for healthcare expenditures, there is a need for diagnostic products that balance efficiency and cost-effectiveness. The founding team of Junyuan Bio possesses substantial technical expertise and industry experience, enabling them to leverage their technological strengths in alignment with clinical needs in China to develop diagnostic products with significant advantages in performance metrics and cost of use. Furthermore, the superior performance of Junyuan Bio’s technology platform allows for further expansion of its R&D pipeline. We are pleased to participate in Junyuan Bio’s growth and look forward to seeing it emerge as a globally leading enterprise in innovative diagnostic technologies.”

Yanghe Investment is a venture capital firm jointly established by several publicly listed companies in the healthcare sector. Focusing on investments in the medical industry, Yanghe Investment has, since its inception in 2013, successively invested in numerous high-quality healthcare enterprises, including Vishee Medical, Mingkang Medical, Libo Pharmaceutical, Kanglu Biotechnology, Nuore Medical, Ruitong Biotechnology, and Respray.